Which P2Y12 inhibitors are appropriate choices in NSTEMI?

Unlock all questions

This demo includes only 20 questions. Upgrade to access hundreds of questions, flashcards, exam simulations, and disable ads.

Full question bankExam simulationsFlashcards
From $24.99Unlock all

Study for the Clinical Decision-Making (CDM) Cases Part I Test. Engage with challenging scenarios and questions, complete with hints and explanations for better understanding. Prepare thoroughly for your exam!

Multiple Choice

Which P2Y12 inhibitors are appropriate choices in NSTEMI?

Explanation:
In NSTEMI, dual antiplatelet therapy is used, combining aspirin with a P2Y12 inhibitor to prevent further platelet activation and thrombus formation. The P2Y12 inhibitors available include clopidogrel, prasugrel, and ticagrelor. Abciximab is a GP IIb/IIIa inhibitor, not a P2Y12 blocker, and aspirin is not a P2Y12 inhibitor. Among the given options, clopidogrel and ticagrelor are the P2Y12 inhibitors, making that choice the correct one. The option mentioning prasugrel only is incomplete because prasugrel is also a P2Y12 inhibitor and can be used depending on patient factors.

In NSTEMI, dual antiplatelet therapy is used, combining aspirin with a P2Y12 inhibitor to prevent further platelet activation and thrombus formation. The P2Y12 inhibitors available include clopidogrel, prasugrel, and ticagrelor. Abciximab is a GP IIb/IIIa inhibitor, not a P2Y12 blocker, and aspirin is not a P2Y12 inhibitor. Among the given options, clopidogrel and ticagrelor are the P2Y12 inhibitors, making that choice the correct one. The option mentioning prasugrel only is incomplete because prasugrel is also a P2Y12 inhibitor and can be used depending on patient factors.

More Multiple Choice Questions
Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy